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Myofibroblast accumulation, subepithelial fibrosis, and vascular re-
modeling are complicating features of chronic asthma, but the mech-
anisms are not clear. Platelet-derived growth factors (PDGFs) regulate
the fate and function of various mesenchymal cells and have been
implicated as mediators of lung fibrosis. However, it is not known
whether PDGF-BB signaling via PDGFR, which is critical for the
recruitment of pericytes to blood vessels, plays a role in airway
remodeling in chronic asthma. In the present study, we used a
selective PDGFR inhibitor (CP-673451) to investigate the role of
PDGFR signaling in the development of airway remodeling and lung
dysfunction in an established mouse model of house dust mite-
induced chronic allergic asthma. Unexpectedly, we found that phar-
macological inhibition of PDGFR signaling in the context of chronic
aeroallergen exposure led to exacerbated lung dysfunction and airway
smooth muscle thickening. Further studies revealed that the inflam-
matory response to aeroallergen challenge in mice was associated
with decreased PDGF-BB expression and the loss of pericytes from
the airway microvasculature. In parallel, cells positive for pericyte
markers accumulated in the subepithelial region of chronically in-
flamed airways. This process was exacerbated in animals treated with
CP-673451. The results indicate that perturbed PDGF-BB/PDGFR
signaling and pericyte accumulation in the airway wall may contribute
to airway remodeling in chronic allergic asthma.
asthma; house dust mite; airway hyperresponsiveness; pericyte; re-
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ASTHMA IS A HETEROGENIC DISEASE that currently affects 300
million people worldwide (34). Allergic asthma is defined as
an allergen-induced, immune-driven chronic lung disease man-
ifested by recurrent episodes of airway inflammation composed
of infiltrating eosinophils, mast cells, macrophages, neutro-
phils, and lymphocytes (1). Airway remodeling is thought to be
facilitated by this chronic inflammatory process (5). The struc-
tural changes associated with airway remodeling comprise
goblet cell hyperplasia, collagen deposition, and increased
airway smooth muscle (ASM) mass, all of which contribute to
the clinical manifestation of lung dysfunction (1). Inflamma-
tory cytokines and the profibrogenic growth factor transform-
ing growth factor- (TGF-) are believed to play significant
roles in driving these structural changes. However, the signal-
ing mechanisms and the cellular sources from which the
increased mesenchymal cell population of the airway wall is
derived have not been fully described. Some studies have
demonstrated that bone marrow-derived fibrocytes contribute
to airway wall remodeling (30, 31), whereas others have
suggested a minimal role for these cells (24). Additionally, the
differentiation of mesenchymal cells from airway epithelial
cells via epithelial-to-mesenchymal transition has been shown
to be a mechanism of remodeling in a mouse model of severe
allergic airway disease (20).
The platelet-derived growth factors (PDGFs) are mitogens
for a number of mesenchymal cell types, including fibroblasts
and smooth muscle cells (9). The receptors of the PDGFs,
PDGF receptor alpha (PDGFR) and PDGF receptor beta
(PDGFR), are tyrosine kinases and are thus amenable to
pharmacological intervention. However, little is known regard-
ing the expression of the PDGFs in asthma, since the limited
studies available in the literature have documented few differ-
ences in PDGF or PDGF receptor expression in human asth-
matic patients compared with healthy controls (3, 6, 15, 25).
Specifically focusing on PDGF-BB and its cognate receptor
PDGFR in the context of allergic airway disease, stimulation
of ASM cells with PDGF-BB in vitro has been shown to act in
concert with TGF- to stimulate cell migration (18). Moreover,
a recent study using an adenovirus vector to overexpress
PDGF-BB in the airway epithelium in an ovalbumin (OVA)-
driven mouse model of asthma was shown to induce ASM cell
proliferation and enhance airway hyperresponsiveness (AHR)
(14). PDGF receptors are also expressed on vascular mural
cells, a heterogeneous population of mesenchymal cells that
line the outer surface of microvessels and are therefore abun-
dant in the lung (2). Pericytes, the population of mural cells
covering capillaries, express desmin and NG2 but are negative
for -smooth muscle actin (-SMA), whereas mural cells
covering arterioles and venules express desmin and -SMA
and are termed vascular smooth muscle (VSM) cells (2). Mural
cells are recruited to and retained on blood vessels through
PDGF-BB/PDGFR interactions (reviewed in Ref. 2). Im-
paired pericyte coverage of blood vessels is seen in PDGF-
BB-deficient mice and in diseases like cancer and is associated
with vascular leakage and edema (2, 4, 32).
In light of these findings, and since tyrosine kinase inhibitors
such as masitinib are currently being investigated as asthma
therapies (16), we elected to investigate the impact of
PDGFR inhibition on airway and VSM cells/pericytes in a
mouse model of chronic aeroallergen exposure driven by
exposure to house dust mite (HDM) extract via the respiratory
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mucosa. HDM exposure is strongly associated with human
asthma and is one of the most ubiquitous respiratory allergens
worldwide. In mice, chronic respiratory HDM exposure leads
to Th2-polarized airway inflammation, remodeling of the air-
way wall and bronchial hyperreactivity, and thus recapitulates
many of the features of clinical asthma (21). Using this para-
digm, we investigated the role of PDGFR signaling and the
downstream effects of inhibiting this receptor during chronic
HDM exposure on airway remodeling and lung dysfunction.
MATERIALS AND METHODS
Animal handling. Female C57Bl/6 mice were bred in-house at the
Karolinska Institutet animal facility at the Department of Mikrobi-
ologi, Tumör- och Cellbiologi or purchased from Harlan Laboratories
(Wyton, UK) and housed at the central animal facility at Imperial
College London. Transgenic mice used for pericyte lineage tracing
studies [Tg(Cspg4-DsRed.T1)1Akik/J] were obtained from the Jack-
son Laboratories (Bar Harbor, ME); the phenotype of these mice was
determined by direct fluorescent imaging of the DsRed fluorescent
signal in ear biopsies. Animals were initiated into experiments at 8–12
wk of age. Mice were housed under specific pathogen-free conditions
following a 12-h light-dark cycle and were provided food and water
ad libitum. All experiments described in this study were approved by
the Research Ethics Committees at the Karolinska Institute and at
Imperial College London and were performed in accordance with the
UK Home Office and Imperial College London guidelines on animal
welfare.
Antigen and drug administration. Mice were challenged with
purified Dermatophagoides pteronyssinus extract (HDM) (Greer Lab-
Table 1. Antibodies used to stain tracheobronchal whole mounts and lung sections
Application Antibody Supplier Catalog Number Concentration
Immunofluorescence: Lung sections
Primary antibodies Rabbit anti-mouse NG2 Millipore AB5320 1:200
Cy3-conjugated anti--smooth muscle
actin
Sigma-Aldrich C6198 1:1,000
FITC-conjugated anti--smooth muscle
actin
Sigma-Aldrich F3777 1:500
Armenian hamster anti-mouse CD31 Abcam ab78739 1:500
Immunofluorescence: Tracheas
Primary antibodies Rabbit anti-mouse NG2 Millipore AB5320 1:500
Cy3-conjugated anti--smooth muscle
actin
Sigma-Aldrich C6198 1:1,000
Rabbit anti-mouse desmin Abcam ab6570 1:400
Rat anti-mouse anti-E-cadherin Thermo Scientific/Pierce MA1-25160 1:500
Armenian hamster anti-mouse CD31 Abcam ab78739 1:400
Immunofluorescence
Secondary antibodies Alexa Fluor 488-conjugated 2° antibody
goat anti-rat
Jackson
ImmunoResearch
111-545-143 1:500
Alexa Fluor 488-conjugated 2° antibody
goat anti-rabbit
Jackson
ImmunoResearch
111-545-144 1:500
Alexa Fluor 546-conjugated 2° antibody
goat anti-rabbit
Invitrogen A-11035 1:500
Alexa Fluor 647-conjugated 2° antibody
goat anti-Armenian hamster
Jackson
ImmunoResearch
127-605-099 1:500
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Fig. 1. A: schedule of allergen dosing and
drug delivery in the house dust mite (HDM)
model. Bronchoalveolar lavage (BAL) was
collected after 3 wk of HDM exposure to
assess the severity of inflammation (B) and
the proportion of eosinophils (C) recruited
to the airways of saline (SAL) and HDM-
exposed mice [intranasally (i.n.) 5 days/wk
for 3 wk] treated daily with a PDGFR
inhibitor (CP-673451; CP) or vehicle (PEG-
400; VEH); n  5 mice per group. *P 
0.05; n.s., not significant.
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oratories, Lenoir, NC) 5 days/wk for 3 or 5 consecutive wk. HDM was
resuspended in sterile phosphate-buffered saline (PBS) (2.5 mg of
protein/ml); 10 l of HDM were administered intranasally to isoflu-
rane-anesthetized mice (Sigma-Aldrich, Gillingham, UK) (21). Con-
trol mice were subjected to the same exposure protocol but received
PBS (10 l). In each group, a subset of animals received a selective
PDGFR inhibitor [1-(2-(5-(2-methoxy-ethoxy)-benzoimidazol-1-
yl)-quinolin-8-yl)-piperdin-4-ylamine (CP-673451); Pfizer, New
York, NY] by oral gavage [33 mg/kg in polyethyleneglycol 400
(PEG-400); Sigma-Aldrich] daily for a period of 5 consecutive wk.
Other animals received the drug vehicle (PEG-400). CP-673451 has
10-fold higher affinity for PDGFR vs. PDGFR and greater than
450-fold higher affinity for PDGFR vs. c-Kit and was prepared
according to the procedures described previously (27).
Lung function measurements. After 5 wk of allergen and drug
administration, mice were subjected to lung function measurements
(8). Mice were injected intraperitoneally with pentobarbital sodium
(50 mg/kg) (Sigma-Aldrich), followed by an intramuscular injection
of ketamine (90 mg/kg) (Sigma-Aldrich) (29). Mice were tracheos-
tomized with a 19-gauge blunt-ended needle. Measurements of dy-
namic AHR and elastance were acquired by use of the flexiVent
system (Scireq, Montréal, Canada). Mice were ventilated, and airway
resistance and elastance were calculated as previously described (29).
A 4- to 6-m nebulizer was used, and the duration of nebulization was
10 s per dose. A 50% duty cycle was used during nebulization.
Fluctuations in AHR and elastance were determined by the responses
of the total respiratory system to increasing concentrations (10–300
mg/ml) of methacholine (MCh) (Sigma-Aldrich) delivered into the
inspiratory line of the flexiVent ventilator. The Pao (pressure at airway
opening) waveform was monitored throughout flexiVent data acqui-
sition and was found to be similar during measurements as when the
initial calibration was performed before running each subject. Mea-
surements were not taken when there were obvious signs of respira-
tory effort. Following flexiVent data acquisition, the thoracic cavity of
each mouse was opened to confirm that cardiac arrest had not
occurred.
Collection of specimens. Mice were humanely euthanized and the
lungs were dissected. In some experiments, bronchoalveolar lavage
(BAL) was collected (0.45 ml of PBS). BAL cells were counted by
use of a hemocytometer, centrifuged at 1,200 rpm for 5 min, then
mounted on glass slides by use of a Cytospin (Thermo Scientific,
Hemel Hempstead, UK) and stained with hematoxylin and eosin for
differential cell counts. BAL supernatants were stored at 20°C, then
submitted to ELISA to determine mouse PDGF-BB expression ac-
cording to the manufacturer’s instructions (R&D Systems, Abingdon,
UK). In other experiments, mice were perfused through the left
ventricle with 1% paraformaldehyde, and the trachea, extrapulmonary
bronchi, and lung were dissected out. The tracheas, extrapulmonary
bronchi, and lungs were isolated and preserved in 1% paraformalde-
hyde for 30 min, then transferred to PBS. The lung was embedded in
Optimal Cutting Temperature compound, stored at 80°C, and cut
into 10-m-thick sections for staining. Fresh lung samples were
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Fig. 2. Airway hyperreactivity was assessed by using the flexiVent system in mice exposed to either sterile saline or HDM (25 g) intranasally for 5 wk (5
days/wk) and treated daily with a PDGFR inhibitor (CP-673451) or vehicle (PEG-400). Airway hyperresponsiveness to increasing doses of aerosolized
methacholine (A), airway reactivity (the slope of the dose-response curve) (B), airway elastance (C), and airway compliance (D) were measured. *P  0.05 vs.
SALVEH, #P  0.05 vs. HDMVEH; n  4–6 mice per group.
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snap-frozen for quantitative PCR (qPCR) and immunoblotting exper-
iments.
Immunoblotting. Frozen lung tissue specimens were homogenized
in 400 l of lysis buffer, which was composed of T-PER Tissue
Protein Extraction Reagent (Rockford, IL) supplemented with pro-
tease inhibitors (Complete Mini tablets from Roche Diagnostics
Scandinavia, Bromma, Sweden), and homogenized with a homoge-
nizer (Percell, Stockholm, Sweden). Protein samples were separated
by SDS-PAGE on 4–12% polyacrylamide gels and blotted onto
nitrocellulose membranes. The membranes were incubated in block-
ing buffer (5% skim milk) in Tris-buffered saline containing 0.5%
Tween for 1 h at room temperature and probed with a polyclonal
rabbit anti-human PDGF-BB antibody (Aviva Systems Biology, San
Diego, CA) diluted 1:1,000 in blocking buffer. After washing, the
membranes were incubated with a horseradish peroxidase-conjugated
secondary anti-rabbit antibody (GE Healthcare, Stockholm, Sweden)
diluted 1:5,000 in blocking buffer, for 1 h at room temperature. The
membranes were developed using ECL detection reagent (Amer-
sham, GE Healthcare). To ascertain equal loading of protein, the
membranes were stripped and reprobed with a rabbit anti-mouse
antibody against Akt (Cell Signaling/BioNordika Sweden, Stockholm,
Sweden) diluted 1:1,000 in blocking buffer.
Immunofluorescent staining. Lung sections from C57Bl6 and
DsRed-NG2 mice were warmed to room temperature and nonspecific
binding was blocked by incubating in 5% normal goat serum (NGS),
0.3% Triton X-100 and 0.1% bovine serum albumin (BSA) (all
purchased from Sigma-Aldrich) in PBS for 1 h at room temperature.
Sections were stained using the appropriate primary (overnight) and
secondary (1 h) antibodies (Table 1). After being washed twice in
PBS, sections were mounted by use of a glycerol-based mounting
medium containing DAPI (Vector Laboratories, Peterborough, UK) to
visualize DNA. For polyclonal antibodies, negative reagent controls
were carried out.
For tracheobronchial whole-mount immunostaining, the trachea
and extrapulmonary bronchi were dissected and cleaned of connective
tissue and mounted on Kwikgard-coated (WPI, Sarasota, FL) six-well
culture plates. Nonspecific binding was blocked by incubating trachea
sections in 5% NGS, 0.3% Triton X-100, and 0.2% BSA in PBS
overnight. Left and right trachea sections were stained using the
appropriate primary and secondary antibodies overnight at room
temperature (Table 1). Sections were washed thrice in PBS and
mounted using a glycerol-based mounting medium containing DAPI
(Vector Laboratories). For all antibodies, negative reagent controls
were carried out with no staining observed.
Light microscopy. Quantification of -SMA- and NG2-positive
cells in the trachea and extrapulmonary bronchi was performed with
a Leica DM2500 fluorescence microscope (Leica Microsystems, Mil-
ton Keynes, UK). Counts were normalized to the length of each
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Fig. 3. A–D: immunostaining of lung sections was performed with an -smooth muscle actin antibody (-SMA, red) to assess smooth muscle mass in the region
of interest (ROI; 40 m distal to the subepithelial basement membrane) of the large airways (AW) in saline and HDM-exposed mice (i.n. 5 days/wk for 5 wk)
treated daily with a PDGFR inhibitor (CP-673451) or vehicle (PEG-400). Solid white line indicates the subepithelial basement membrane. Scale bar 10 m.
E: morphometric analysis of -SMA staining in the airways of saline and HDM-exposed mice (i.n. 5 days/wk for 5 wk) treated daily with a PDGFR inhibitor
(CP-673451) or vehicle (PEG-400). *P  0.05, n  5–7 from 2 independent experiments.
Fig. 4. A–L: whole-mount immunostaining for -SMA (red) and the microvasculature in the extrapulmonary bronchus (CD31, blue) in relation to the airway
epithelium (E-cadherin, green) was performed to determine the location -SMA cells in the bronchus in saline and HDM-exposed mice. Arrows (C and D)
indicate subepithelial -SMA cells and arrowheads indicate gaps in the pericyte coverage of vessels. H and L: Z-stack confocal imaging was performed to assess
the 3-dimensional location of -SMA cells in the bronchus in saline- and HDM-exposed mice. M: quantification of subepithelial -SMA cells in the bronchus
after 3 and 5 wk of saline or HDM exposure. *P  0.05; n  5–10 mice per group from 3 independent experiments. Scale bars 50 m (A and B), 25 m (C,
E–G, I–K), and 12.5 m (D, H, L).
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tracheobronchial whole mount (including the extrapulmonary bronchi
at the distal end of the preparation). For image acquisition from
immunostained tracheobronchial whole mounts and lung sections,
1,024 	 1,024 pixel RGB-color images were obtained by using a
Zeiss LSM 510 inverted confocal microscope with argon, helium-
neon, and UV lasers (Carl Zeiss, Göttingen, Germany) using an EC
Plan-Neofluar 	40/1.30 oil objective with the DIC phase contrast
technique (10). Using the optimized pinhole size, 0.9-m-thick opti-
cal sections were sequentially collected with a step size of 1 m (lung
sections) or 1.5 m (tracheas). Image analysis was performed by use
of Zeiss AIM 3.2.2 software and Zeiss LSM Image software (Carl
Zeiss AG). Three-dimensional visualizations (Supplemental Videos
S1–S4; Supplemental Material for this article is available on the
Journal website) of confocal images were prepared with Volocity
software (Perkin-Elmer, Waltham, MA). Morphometric analysis of
ASM thickness was performed by a blinded observer on -SMA-
stained lung sections and analyzed with ImageJ software (NIH).
Morphometric analysis of the number of NG2 cells in the airway
subepithelial region was conducted by a blinded observer on lung
sections stained for NG2, -SMA, and CD31 (to prevent enumeration
of pericytes associated with the microvasculature). Five representative
images were taken of the large airways (bronchi and bronchioles)
from each animal (n  5–10 per group from two independent
experiments). Images were taken on a Zeiss LSM 510 inverted
confocal microscope and processed by using ImageJ. NG2 cells in
the airway subepithelial region were enumerated and counts were
normalized to millimeters of basement membrane.
qPCR. Whole tissue RNA from lung was isolated with TRIzol
reagent (Invitrogen/Life Technologies, Stockholm, Sweden) and QIA-
GEN RNeasy (Qiagen, Sollentuna, Sweden) according to the manu-
facturers’ instructions. Total RNA (1 g) was reverse transcribed
according to the manufacturer’s instructions (iScript cDNA synthesis
kit, Bio-Rad). qPCR was performed by using Platinum SYBR green
SuperMix (Invitrogen) and 25 ng cDNA per reaction. Primers used
were Pdgfb QT00266910, Pdgfrb QT00113148, and L19
QT01779218. Ct values for the three genes analyzed were 19–20
(PDGF-BB), 24–26 (PDGFR), and 17–18 (L19). Expression levels
were normalized to the expression of L19. Melt curves were assessed
following the completion of RT-PCR to ensure that the fluorescent
signal resulted from a single PCR product.
Data analysis. Data were analyzed with GraphPad Prism Software
version 6 (GraphPad Software, San Diego, CA). Statistical analysis
was performed by Student’s t-test or one-way ANOVA with a sub-
sequent Tukey’s post hoc test where appropriate. Differences were
considered statistically significant when P 0.05. Pearson correlation
analysis was performed to assess the relationship between the degree
of ASM thickening and numbers of cells. Results are presented as
means 
 SE.
RESULTS
PDGFR blockade exacerbates airway hyperresponsive-
ness driven by chronic HDM exposure. To evaluate the impact
of impaired PDGFR signaling on allergic inflammation, we
treated mice with the tyrosine kinase inhibitor CP-673451,
which selectively inhibits PDGFR (27), in the context of
HDM exposure for a period of 3 consecutive wk (Fig. 1A).
Systemic administration of CP-673451 did not have any effect
on the degree of airway inflammation or the proportion of
eosinophils in the BAL of mice exposed to saline or HDM for
3 wk (Fig. 1, B and C). To determine the physiological impact
of respiratory HDM exposure and systemic CP-673451 treat-
ment, lung function was assessed in mice exposed to saline or
HDM for 5 wk (
CP-673451) in response to aerosolized MCh.
Airway resistance and elastance were measured in control
animals (PBSVEH; PBSCP), in HDM-exposed mice
(HDMVEH), as well as in HDM-exposed mice treated with
CP-673451 (HDMCP). CP-673451 had no significant effect
on lung function in the saline control groups (SALVEH and
SALCP) (Fig. 2, A–D). Relative to control mice,
HDMVEH animals demonstrated significantly higher airway
resistance (P  0.05), and, compared with HDMVEH mice,
HDMCP-exposed animals demonstrated significantly in-
creased airway resistance (P  0.05) (Fig. 2A). Airway reac-
tivity [calculated as the slope of the MCh dose-response curve
from baseline to the peak of the dose-response curve, as
previously described (23)] showed an increased trend in the
HDM group relative to control (P 0.05) but was significantly
increased in HDMCP-exposed animals (P  0.05) (Fig. 2B).
Maximal airway elastance was significantly greater in HDM-
exposed mice vs. the control animals (P  0.05) (Fig. 2C);
conversely, airway compliance was significantly lower in the
HDM groups vs. the saline control groups (P  0.05) (Fig.
2D). No differences in airway elastance or compliance were
found between the HDMVEH and HDMCP groups (Fig. 2,
C and D).
PDGFR blockade during HDM exposure promotes ASM
mass thickening. The lung function results suggested that
inhibition of PDGFR signaling exacerbated disease in HDM-
exposed mice, so we performed a morphometric analysis of
ASM mass (Fig. 3, A–D). Quantification of the -SMA
stained area in the subepithelial region of the large airways
revealed a significant increase in ASM mass in HDM-VEH
mice, which was increased further in HDM-CP mice (Fig. 3E).
Loss of vascular smooth muscle cells upon HDM exposure.
Since PDGFR signaling plays a vital role in the recruitment
of mural cells to blood vessels we next examined whether
mural cell coverage of airway blood vessels was affected
during HDM-induced airway inflammation. We performed
whole-mount staining of extrapulmonary bronchi with markers
against CD31, -SMA, and E-cadherin to visualize endothelial
cells, vascular smooth muscle cells, and epithelial cells, respec-
tively; negative control whole mounts (omission of the primary
antibodies) were negative for all markers (data not shown).
Confocal microscopy analysis of stained specimens revealed
marked changes in the association of -SMA VSM cells with
airway blood vessels in HDM-exposed animals. Under nonin-
flammatory conditions, -SMA VSM cells were tightly as-
sociated with arterioles and venules in the mouse airways
(Fig. 4A, Supplemental Video S1). Following HDM exposure,
-SMA cells that were not associated with vessels were
Fig. 5. A–H: immunostaining of the trachea and extrapulmonary bronchus for NG2 (green), -SMA (red), and CD31 (blue) with Z-stack confocal imaging was
performed to assess the 3-dimensional location of pericytes and the distribution of pericyte marker expression in saline and HDM-exposed mice (i.n. 5 days/wk
for 5 wk). Scale bars 25 m. I–P: immunostaining of the trachea and extrapulmonary bronchus for E-cadherin (green), NG2 (red), and CD31 (blue) with Z-stack
confocal imaging was performed to assess the 3-dimensional location of pericytes in the bronchus of saline and HDM-exposed mice (i.n. 5 days/wk for 5 wk).
Scale bars 25 m (I–K, M–O) and 12.5 m (L and P). Quantification of subepithelial (Q) and vessel-associated (R) NG2 cells in the bronchus after 5 wk of
saline or HDM exposure. **P  0.01, ***P  0.001; n  10 mice per group from 2 independent experiments.
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identified in the mouse airways (Fig. 4, B–D). High-magnifi-
cation imaging analysis indicated the loss of -SMA VSM
cells from airway blood vessels (Fig. 4D, Supplemental Video
S2). Further studies demonstrated tight association of VSM
cells with the microvasculature in control mice and the pres-
ence of -SMA cells close to the airway subepithelium in
HDM-exposed mice (Fig. 4, E–L). Quantification showed a
significant increase in the number of subepithelial -SMA
positive cells in mice exposed to HDM for 3 wk, which
increased further following 5 wk of HDM exposure (Fig. 4M).
Loss of NG2 pericytes upon HDM exposure. Next, we
stained whole-mount preparations of extrapulmonary bronchi
for the pericyte marker NG2 as well as -SMA to characterize
this cell population under normal conditions (Fig. 5, A–D) and
following HDM exposure (Fig. 5, E–H); negative control
whole mounts (omission of the primary antibodies) were neg-
ative for all markers (data not shown). Confocal imaging
revealed that pericytes associated with the airway microvascu-
lature were -SMA/NG2 (Fig. 5A, white arrow), -SMA/
NG2 (Fig. 5E, black arrow), or -SMA/NG2 (Fig. 5E,
white arrowhead); all populations of pericytes appeared to be
more loosely associated with the airway microvasculature
following 5 wk of HDM exposure (Fig. 5E). Further experi-
ments showed that NG2 pericytes were tightly associated
with airway capillaries under baseline conditions (Fig. 5, I–L,
Supplemental Video S3). Following 5 wk of HDM exposure,
NG2 cells appeared to be lost from the microvasculature (Fig.
5, M–P, Supplemental Video S4). In parallel, NG2 cells were
detected below the airway epithelium (Fig. 5N). Quantification
confirmed that the number of vessel-associated NG2 cells
was decreased while the number of subepithelial NG2 cells
was increased in the extrapulmonary bronchi in HDM-exposed
mice vs. control mice (Fig. 5, Q and R).
Accumulation of NG2 cells in the airway wall upon HDM
exposure. To further assess the localization of pericytes in the
airways and how it was affected by HDM exposure, NG2,
-SMA, and CD31 immunostaining was performed on frozen
lung sections; negative control lung sections (omission of the
primary antibodies) were negative for all markers (data not
shown). In control animals, pericytes were localized exclu-
sively around pulmonary blood vessels and associated with
alveolar capillaries (Fig. 6, A–D). In mice exposed to HDM
(Fig. 6, E–L), NG2 cells were found associated with mi-
crovessels (indicated by arrowheads; Fig. 6M). Moreover,
NG2/-SMA cells (indicated by black arrows) and NG2
cells (indicated by white arrows; Fig. 6M) were found in the
Fig. 7. Pericyte localization was assessed in ear biopsies (A and B) and in the lungs (C and D) of wild-type and Tg(Cspg4-DsRed.T1)1Akik/J saline control mice
by direct imaging of the DsRed fluorescent signal. The identity of DsRed-positive cells in the lungs was assessed by colocalization of the signal in -SMA
(E–H) and NG2-expressing (I–L) pericytes in the pulmonary blood vessels (BV). Immunostaining of lung sections from DsRed-NG2 transgenic mice for -SMA
(green), DsRedNG2 pericytes (red), CD31 (white), and cell nuclei (DAPI; blue) was performed in saline control (M–O) and HDM-exposed (P–R) mice (i.n.
5 days/wk for 5 wk). White arrows indicate DsRed-NG2 cells present in the lung parenchyma (E, F, M), black arrow indicates DsRed-NG2/-SMA cells
present in the airway smooth muscle (ASM) bundles (P), and arrowheads indicate microvessel-associated DsRedNG2 cells (F, I). Scale bars 25 m (A–R).
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airway subepithelial region, associated with smooth muscle
bundles surrounding the large airways. Morphometric analysis
of five representative images from saline- and HDM-exposed
mice revealed a statistically significant increase in the number
of NG2 cells that were not associated with the microvascu-
lature in the airway wall following 5 wk of HDM exposure
(Fig. 6N, P  0.001).
To further study the effect of HDM on pericyte localization
in the mouse airways, we used transgenic NG2DsRedBAC
reporter mice [Tg(Cspg4-DsRed.T1)1Akik/J]. These mice ex-
press the red fluorescent protein DsRed.T1 under the control of
the mouse NG2 (Cspg4) promoter and were thus used to
interrogate whether pericytes accumulate in the ASM follow-
ing chronic HDM exposure (Fig. 7). The genotype of the mice
was confirmed by observation of ear biopsies under a fluores-
cent microscope; bright red NG2 cells were observable sur-
rounding the base of hair follicles in transgene-bearing mice
(Fig. 7, A and B). We were able to observe DsRed-NG2 cells
in the walls of large vessels (Fig. 7, D–H), and DsRed-NGS
cells were also positive for NG2 by antibody-mediated staining
(Fig. 7, I–L). DsRed-NG2 cells were absent from the ASM
bundles of saline control mice (Fig. 7, M–O), whereas clusters
of DsRed-NG2 cells were clearly visible within the ASM
bundles of mice exposed to HDM for 5 wk (Fig. 7, P–R).
Reduced lung PDGF-BB expression and PDGFR signaling
in HDM mice. We next assessed the expression of PDGF-BB
and PDGFR in the lungs of mice exposed to saline or HDM
on the mRNA and protein levels. qPCR analysis of PDGF-BB
and PDGFR expression in the lung revealed no changes in the
expression of these genes after 5 wk of HDM compared with
saline mice (Fig. 8A). ELISA performed on BAL supernatants
revealed significantly less PDGF-BB expression in the airways
of mice exposed to HDM for 3 or 5 wk compared with control
mice (Fig. 8B). Immunoblotting analysis showed unaltered
levels of the PDGF-BB precursor in lungs from HDM mice vs.
saline mice (Fig. 8C). However, a significant decrease in the
cleaved, active form of PDGF-BB was found in HDM-exposed
mice (Fig. 8D). In line with this, we found that PDGFR
signaling was reduced in the lungs of mice exposed to HDM
for 3 wk and severely compromised after 5 wk (Fig. 8E).
PDGFR blockade exacerbates pericyte loss from blood
vessels. Finally, we wanted to determine whether pericyte loss
from airway blood vessels was exacerbated in mice exposed to
HDMCP mice vs. HDM-VEH. Confocal microscopy analy-
sis of whole-mount preparations of extrapulmonary bronchi
indicated that fewer -SMA (Fig. 9, A–F) and NG2 (Fig. 9,
G–L) cells were associated with the airway microvasculature in
mice exposed to HDMCP mice vs. HDM-VEH mice. Quan-
tification verified an increase of subepithelial -SMA and
NG2 cells in HDM-CP mice vs. HDM-VEH mice (Fig. 9, M
and O). No effect on pericyte dissociation from blood vessels
was seen in saline-exposed mice treated daily with CP-673451
vs. mice given the vehicle only. Pearson correlation analysis
demonstrated a moderate but significant correlation between
the numbers of subepithelial -SMA VSM cells (Fig. 9N) and
NG2 cells pericytes (Fig. 9P) and the degree of ASM thick-
ening.
DISCUSSION
Chronic allergic asthma is a complex disease provoked by
aeroallergen exposure, which promotes Th2-polarized airway
inflammation (13) and airway remodeling (1), for which a
number of possible underlying mechanisms have been pro-
posed (7, 12, 19, 20, 22, 26, 30). We aimed to investigate the
impact of PDGFR inhibition on HDM-induced allergic air-
way disease in mice. HDM exposure resulted in increased
airway resistance, increased elastance, and reduced compliance
(Fig. 2), in agreement with previous studies showing that
airway inflammation and remodeling contribute to AHR (21).
However, HDM-exposed animals treated with CP-673451 pre-
sented worse lung dysfunction, with increased maximal respi-
ratory resistance and airway reactivity compared with HDM-
exposed mice given the vehicle (Fig. 2, A and B). Clear
differences in AHR were observed between the HDM-exposed
groups, suggesting that impaired PDGFR signaling promotes
lung dysfunction under chronic inflammatory conditions. To
investigate this, we evaluated ASM thickening in these ani-
mals. Rather than the expected reduction in ASM thickening,
since PDGF-BB is known to be a smooth muscle mitogen (9),
we instead observed increased ASM thickening in mice ex-
posed to HDM and treated with the PDGFR inhibitor (Fig. 3).
Since PDGFR signaling is critical for endothelial-pericyte
cell interactions, we studied whether airway microvessel-asso-
ciated pericytes may have contributed to airway remodeling by
being recruited to the airway wall. These experiments showed
the loss of -SMA cells from the microvasculature of the
bronchi and accumulation of these cells in the subepithelial
region of the airway wall (Fig. 4). To confirm that these cells
were indeed pericytes and not tissue fibroblasts acquiring a
myofibroblast phenotype, we assessed the localization of
NG2 pericytes and observed the accumulation of the cells in
the subepithelial region of the large airways as well, similar to
what was observed with -SMA pericytes (Fig. 5). Moreover,
NG2 pericytes appeared to be incorporated into ASM bundles
in mice exposed to HDM (Fig. 6). Lineage tracing experiments
with DsRed-NG2 mice, in which pericytes expressing NG2
exhibit a red fluorescent marker, confirmed the presence of
pericytes within the ASM bundles of mice exposed to HDM
(Fig. 7). These results suggest that pericytes may represent a
source of airway-resident mesenchymal cells that can contrib-
ute to airway remodeling in chronic asthma. However, an
alternative process could also be considered to explain these
findings, since a change in the phenotype in airway wall
resident mesenchymal cells (i.e., fibroblasts) may have oc-
curred with the acquisition of pericyte markers such as NG2.
Although the expression levels of PDGF-BB mRNA and
pro-PDGF-BB were not significantly altered in HDM-exposed
Fig. 9. Whole-mount trachea and extrapulmonary bronchus immunostaining for -SMA (red), desmin (green), and CD31 (blue) (A–F) or NG2 (red) and CD31 (green)
(G–L) was performed with Z-stack confocal imaging (D–F, J–L) to determine the location of pericytes in the bronchus of saline and HDM-exposed mice (i.n. 5 days/wk
for 5 wk) treated daily with a PDGFR inhibitor (CP-673451) or vehicle (PEG-400). Quantification and Pearson correlation with ASM thickness of subepithelial
-SMA cells (M and N) and NG2 cells (O and P) in the bronchus after 5 wk of saline or HDM exposure in mice treated daily with a PDGFR inhibitor (CP-673451)
or vehicle (PEG-400). White arrows indicate pericytes that have detached from blood vessels. *P  0.05; n  5–7 mice per group from 2 independent experiments.
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mice compared with control mice, the amount of processed,
active PDGF-BB was reduced in the lungs of HDM exposed
mice (Fig. 8), providing a mechanism to explain the observed
change in pericyte location. This suggests that the activity of
one or more pro-PDGF-BB convertases may have been inhib-
ited during the allergic inflammatory response driven by HDM
exposure. Several proteinases have been reported to cleave
pro-PDGF-BB into its active form and it would be interesting
in the future to study their role in regulating PDGF-BB sig-
naling and pericyte biology in allergic asthma (33).
In support of reduced PDGF-B/PDGFR signaling as a
mechanism promoting pericyte loss from the microvasculature
and airway remodeling, we found increased pericyte loss in the
extrapulmonary bronchi when HDM-exposed mice were treated
daily with CP-673451 (Fig. 9). These results resemble data
from a recent study using a model of airway inflammation in
the mouse evoked by inoculation with Mycoplasma pulmonis
bacteria. In that study, loss of pericyte coverage from airway
blood vessels was observed during the first week after infection
and was associated with reduced expression of PDGF-BB (10).
Pharmacological inhibition of PDGF-BB with a selective
PDGF-BB aptamer exaggerated pericyte loss and led to more
severe Mycoplasma pulmonis infection.
Our results demonstrate that PDGF-B/PDGFR signaling is
important not only for recruitment of pericytes to blood vessels
during development, but also to maintain pericyte attachment
to blood vessels in adult tissues. Reduced PDGF-B/PDGFR
signaling in inflamed tissues might weaken endothelial cell-
pericyte interactions and, subsequently, promote pericyte loss
from blood vessels. It remains to be determined which driving
forces attract pericytes toward inflamed airways. A number of
cytokines and chemokines are overexpressed in asthmatic air-
ways and are under investigation in this model.
Recently, pericytes were identified as a source of myofibro-
blasts in a mouse model of inflammatory kidney fibrosis (17,
24), during scar formation in a mouse model of spinal cord
injury (11), as well as in a mouse model of bleomycin-induced
lung fibrosis (28). The results of this study provide further
evidence of a role for pericytes in fibrotic lung disease. Taken
together, these findings led us to propose a role for pericyte
accumulation in the airway wall, where pericytes are incorpo-
rated into the ASM and thereby contribute to AHR in response
to chronic respiratory HDM exposure. The identification of
lung-resident perivascular cell accumulation in the airway wall
provides evidence for a novel mechanism of airway remodel-
ing and ultimately contributes to our knowledge of the pathol-
ogy of chronic allergic asthma. However, elucidation of the
mechanism by which this occurs is at an early stage, and
further studies are needed to determine the chemotactic signals
driving pericyte accumulation in the airway wall, as well as the
ability of these cells to differentiate into a more smooth muscle
cell-like phenotype.
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